Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	A: Faricimab 6 mg Q8W	317
Overall Study	STARTED	B: Faricimab 6 mg PTI	319
Overall Study	STARTED	C: Aflibercept 2 mg Q8W	315
Overall Study	Received at Least One Dose of Study Drug	A: Faricimab 6 mg Q8W	317
Overall Study	Received at Least One Dose of Study Drug	B: Faricimab 6 mg PTI	319
Overall Study	Received at Least One Dose of Study Drug	C: Aflibercept 2 mg Q8W	314
Overall Study	Completed up to Week 56	A: Faricimab 6 mg Q8W	298
Overall Study	Completed up to Week 56	B: Faricimab 6 mg PTI	312
Overall Study	Completed up to Week 56	C: Aflibercept 2 mg Q8W	299
Overall Study	COMPLETED	A: Faricimab 6 mg Q8W	275
Overall Study	COMPLETED	B: Faricimab 6 mg PTI	288
Overall Study	COMPLETED	C: Aflibercept 2 mg Q8W	267
Overall Study	NOT COMPLETED	A: Faricimab 6 mg Q8W	42
Overall Study	NOT COMPLETED	B: Faricimab 6 mg PTI	31
Overall Study	NOT COMPLETED	C: Aflibercept 2 mg Q8W	48

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03622593/flow